ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Authors:
- 28 June 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (26) , 6268-6277
Abstract
TGN1412, a superagonistic CD28-specific antibody, was shown to require Fc-cross-linking or immobilization as a prerequisite to mediate T-cell proliferation and cytokine release in vitro. We used primary human umbilical vein endothelial cells (HUVECs) to study their ability to induce activation of TGN1412-treated T cells. We confirmed that peripheral primary human T cells do not show activation upon stimulation with soluble TGN1412 alone. Nevertheless, cocultivation of TGN1412-treated T cells with HUVECs induced T-cell activation that was further enhanced using cytokine prestimulated HUVECs. Unexpectedly, Fc-FcγR interaction was dispensable for endothelial cell–mediated proliferation of TGN1412-treated T cells. Transwell-culture assays showed that TGN1412-treated T cells need direct cell-to-cell contact to HUVECs to induce proliferation. We found that costimulatory ICOS-LICOS interaction between T cells and endothelial cells is critically involved in TGN1412-mediated effects. Blocking LICOS reduced TGN1412-mediated T-cell proliferation significantly, whereas recombinant LICOS fully conferred TGN1412-mediated T-cell proliferation. Of note, cytokine stimulation enhanced LICOS expression on HUVECs and ICOS-LICOS interaction up-regulated ICOS expression on TGN1412-treated T cells. Hence, we provide a model of positive feedback conferred by ICOS-LICOS interaction between TGN1412-treated T cells and endothelial cells.Keywords
This publication has 41 references indexed in Scilit:
- B7-H2 Is a Costimulatory Ligand for CD28 in HumanImmunity, 2011
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- Mechanisms of costimulationImmunological Reviews, 2009
- Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissuesProceedings of the National Academy of Sciences, 2009
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences, 2008
- Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic AntibodiesPLOS ONE, 2008
- In Vitro Characterization of Five Humanized OKT3 Effector Function Variant AntibodiesCellular Immunology, 2000
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic reviewToxicology, 1995
- OKT3E, AN ANTI-CD3 ANTIBODY THAT DOES NOT ELICIT SIDE EFFECTS OR ANTIIDIOTYPE RESPONSES IN CHIMPANZEESTransplantation, 1991